Restructuring and Cash Management Extend CytomX’s Financial Runway CytomX Therapeutics has enacted a 40% workforce reduction and sharpened clinical priorities, extending its cash runway into Q2 2026. The company ended Q3 2024 with $117.6 million in cash, supporting key programs CX-2051, CX-904, and CX-801, and maintaining partnerships with major pharmaceutical firms.456